Alerts
Holiday Hours Information

In recognition of the Christmas and New Year’s holidays, some of The University of Kansas Cancer Center’s offices will have modified hours on Wednesday, December 25, and Wednesday, January 1.

Skip Navigation

A Phase 3 Randomized Study of Selumetinib versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 NF1 Associated Low-Grade Glioma LGG

Brief Summary

Type:
Brain Tumors / Neurologic Cancers

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT03871257

Study #:
cmh - ACNS1831

Start Date:
Jul 05, 2020

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03871257

View Complete Trial Details & Eligibility at ClinicalTrials.gov